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on primary ependymomas to determine the prevalence 
and prognostic potential of telomerase activity or alter-
native lengthening of telomeres (ALT) as telomere main-
tenance mechanisms, respectively. Imetelstat, a phase 2 
telomerase inhibitor, was used to elucidate the effect of 
telomerase inhibition on proliferation and tumorigenicity 
in established cell lines (BXD-1425EPN, R254), a primary 
TIC line (E520) and xenograft models of pediatric epend-
ymoma. Over 60 % of pediatric ependymomas were found 
to rely on telomerase activity to maintain telomeres, while 
no ependymomas showed evidence of ALT. Children with 
telomerase-active tumors had reduced 5-year progression-
free survival (29 ± 11 vs 64 ± 18 %; p = 0.03) and overall 
survival (58 ± 12 vs 83 ± 15 %; p = 0.05) rates compared 
to those with tumors lacking telomerase activity. Imetelstat 
Abstract Pediatric ependymomas are highly recurrent 
tumors resistant to conventional chemotherapy. Telomer-
ase, a ribonucleoprotein critical in permitting limitless rep-
lication, has been found to be critically important for the 
maintenance of tumor-initiating cells (TICs). These TICs 
are chemoresistant, repopulate the tumor from which they 
are identified, and are drivers of recurrence in numerous 
cancers. In this study, telomerase enzymatic activity was 
directly measured and inhibited to assess the therapeutic 
potential of targeting telomerase. Telomerase repeat ampli-
fication protocol (TRAP) (n = 36) and C-circle assay/
telomere FISH/ATRX staining (n = 76) were performed 
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inhibited proliferation and self-renewal by shortening tel-
omeres and inducing senescence in vitro. In vivo, Imetelstat 
significantly reduced subcutaneous xenograft growth by 
40 % (p = 0.03) and completely abolished the tumorigenic-
ity of pediatric ependymoma TICs in an orthotopic xeno-
graft model. Telomerase inhibition represents a promising 
therapeutic approach for telomerase-active pediatric epend-
ymomas found to characterize high-risk ependymomas.
Keywords Ependymoma · Telomerase · Telomerase 
inhibition · Imetelstat · TRAP
Introduction
Ependymomas represent the third most common central 
nervous system (CNS) tumor in children and mainly arise 
in young children under 5 years of age within the poste-
rior fossa [34, 46]. Pediatric ependymomas are highly 
recurrent and chemoresistant entities that will often recur 
numerous times throughout a patient’s lifetime [32]. Cur-
rent standard of care aims for complete surgical resection 
followed by radiotherapy. However, over 50 % of children 
with gross total resection will still experience tumor recur-
rence despite aggressive multimodal therapy [35]. Fur-
thermore, radiation in young children is associated with 
long-term cognitive sequelae [17, 39]. The only widely 
accepted prognostic factor of outcome is extent of surgical 
resection, while histological grading has proven to be an 
unreliable and poor predictive factor [7, 38]. The lack of 
robust therapeutic and prognostic targets has contributed 
to poor 5-year progression-free survival (PFS) and overall 
survival (OS) rates of 23–45 and 50–64 %, respectively, 
and highlights the urgent need to identify targetable path-
ways in pediatric ependymoma to improve patient out-
comes [17, 39].
Telomeres are regions of repetitive DNA found at the 
end of chromosomes that shorten during cell division due to 
incomplete DNA replication [9]. Following continued pro-
liferation, telomeres erode to a critically short length and 
induce a growth-arrested state known as senescence [10]. 
However, stem cells and over 90 % of cancers express tel-
omerase, which employs its RNA component (hTR) to bind 
to telomeric sequences and synthesize telomeric hexanucle-
otide repeats de novo using a reverse transcriptase domain 
(hTERT), preventing telomere erosion and permitting sus-
tained proliferation [16, 43]. Telomerase has been found to 
be critically important for the maintenance of tumor-initi-
ating cells (TICs), which are chemoresistant cells able to 
repopulate the tumor from which they are identified, and 
drivers of recurrence in numerous cancers [5, 20]. ALT rep-
resents a telomerase-independent mechanism of telomere 
maintenance that relies upon homologous recombination 
machinery to maintain telomeres [3]. Although this mech-
anism is relatively rare in most cancers, ALT appears in 
30–50 % of pediatric and adult high-grade gliomas (HGGs) 
and its prevalence in other brain tumors such as pediatric 
ependymoma is yet to be elucidated [1].
Numerous studies have suggested telomerase contrib-
utes to recurrence in pediatric ependymoma by assessing 
hTERT expression, as it is believed to be the rate-limiting 
factor for telomerase activation. Immunohistochemical 
detection methods have demonstrated that high expression 
levels of the catalytic hTERT subunit predicts poor PFS 
and OS in primary ependymoma both alone and as a model 
of telomere dysfunction [23, 36]. Unfortunately, the anti-
body used in these studies has subsequently been found to 
cross-react with nucleolin and is thus not rigorous enough 
for routine clinical use [44]. Furthermore, hTERT mRNA 
expression was studied and found to be a strong predic-
tor of OS in pediatric ependymoma [25]. However, stud-
ies have found up to a 30 % discordance between hTERT 
mRNA expression and telomerase activity with the latter a 
more sensitive test [19]. Most recently, hypermethylation 
of the hTERT promoter has been associated with increased 
hTERT mRNA expression and has been found to predict 
both PFS and OS in pediatric ependymoma [4]. However, 
the mechanism of hTERT upregulation following promoter 
hypermethylation remains unclear. Although all of these 
studies suggest telomerase represents a prognostic bio-
marker and a therapeutic target in pediatric ependymoma, 
robust detection of telomerase activity is required to defi-
nitely address the importance of telomerase in this tumor 
type.
In this study, we assessed telomerase activity directly 
using the telomerase repeat amplification protocol (TRAP) 
to undeniably determine the prevalence of telomerase as 
a telomere maintenance mechanism in pediatric epend-
ymoma and to determine whether telomerase enzymatic 
activity can predict recurrence. Telomerase activity was 
then directly targeted using the telomerase inhibitor Ime-
telstat [20] in pediatric ependymoma cell models and 
patient-derived xenografts to determine the effect on epend-
ymoma tumor initiating potential.
Our results show that pediatric ependymomas rely 
exclusively on telomerase as a mechanism of telomere 
maintenance and that telomerase activity is associated 
with increased recurrence rates and higher mortality. Fur-
thermore, telomerase inhibition was able to reduce epend-
ymoma growth in vitro and in vivo along with total inhi-
bition of TIC tumorigenicity. These findings suggest that 
telomerase activity may comprise a promising prognostic 
biomarker and a therapeutic target in a tumor type that 
lacks effective prognostic and chemotherapeutic options.
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Materials and methods
Patient samples and clinical data
Patient samples and clinical data used were gathered from 
primary and recurrent pediatric ependymomas operated on 
between 1990 and 2013 at The Hospital for Sick Children 
(Sick Kids, Toronto, ON, CA) following informed consent 
and approval by the institutional Research Ethics Board. 
36 fresh-frozen samples were used for telomerase activ-
ity detection, 97 formalin-fixed, paraffin-embedded (FFPE) 
samples were used for C-circle analyses, telomere FISH 
and ATRX staining, 18 fresh-frozen samples were used for 
hTERT promoter mutational analysis, 24 fresh-frozen and 
FFPE samples were used for hTERT promoter hypermeth-
ylation analysis, 11 FFPE samples were used for C11orf95-
RELA fusion subgrouping and 23 fresh-frozen and FFPE 
samples were used for CIMP subgrouping. Table 1 provides 
a clinical description of the patient cohort used for assessing 
the prognostic potential of telomerase activity, while Table 
S1 provides individual clinical data on all samples used in 
the study where available.
Telomerase repeat amplification protocol (TRAP)
The telomerase activity status of patient samples was 
assessed using the TeloTAGGG Telomerase PCR ELISA 
kit (Roche, Sandhoferstrasse, MA, NE) using 1 μg of 
lysate per sample and appropriate controls as previously 
described [36]. Telomerase activity of cell samples was 
assessed using a modified version of the gel-based TRA-
Peze Telomerase Detection kit (Millipore, Temecula, CA, 
USA) utilizing a Cy5-labeled forward primer (Cy5-ATTC-
CGTCGAGCAGAGTT). In brief, untreated, mismatch 
and Imetelstat-treated cells were lysed using CHAPS lysis 
buffer. Cell extract (1.2 µg), negative control (lysis buffer) 
and positive control extract (provided in kit) were then 
added to the master mix to yield a total volume of 50 μL. 
PCR amplification consisted of incubation at 30 °C for 
30 min, followed by 35 cycles of 94 °C for 20 s, 56 °C for 
30 s and 72 °C for 30 s. Approximately 30 μL of each PCR 
reaction was loaded onto a 12.5 % non-denaturing acryla-
mide gel and run for 4 h at 250 V. Telomerase amplification 
products were imaged using the FluorChem® Q MultiIm-
age III system (ProteinSimple, Santa Clara, Ca, USA). The 
Table 1  Clinical characteristics 
and telomerase activity status of 
pediatric ependymoma cohort
PFS Progression-free survival, 
OS overall survival, SE standard 
error, GTR gross total resection
* Significance as determined by 
log-rank statistics at p ≤ 0.05
Clinical characteristics Patients 5-year PFS 5-year OS
# % % SE Log-rank (p) % SE Log-rank (p)
Age >3 years
 Yes 25 69 51 12 0.36 46 15 0.36
 No 11 31 18 16 36 21
Sex
 Male 26 72 44 13 0.30 45 16 0.20
 Female 10 28 35 16 42 17
Tumor location
 Supratentorial 13 36 32 16 0.16 45 21 0.97
 Infratentorial 23 64 46 13 42 16
Grade
 2 14 39 42 17 0.45 69 19 0.02*
 3 22 61 41 12 25 14
Resection
 GTR 21 58 49 14 0.35 54 17 0.07
 Subtotal 13 36 31 15 33 18
 Biopsy 2 6 50 35 50 35
Radiation
 Yes 25 69 51 12 0.03* 53 16 0.03*
 No 11 31 20 16 21 17
Chemotherapy
 Yes 21 58 40 14 0.94 45 16 0.75
 No 15 42 43 15 41 20
Telomerase activity
 Yes 23 64 29 11 0.03* 58 12 0.05*
 No 13 36 64 18 83 15
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presence of a 6 base-pair banding ladder indicated active 
telomerase.
Taqman genotyping assay
C228T and C250T hTERT promoter mutations were 
assessed in clinical samples and cell lines as previously 
described [28]. 25 ng of sample DNA was run per reaction 
in parallel with mutation-positive DNA serving as a posi-
tive control and sterile water serving as a negative control.
Bisulfite conversion and sequenom mass spectrometry
To determine hTERT promoter hypermethylation and CIMP 
status using sequenom mass spectrometry, DNA isolated 
from either fresh-frozen or FFPE samples was bisulfite con-
verted following kit instructions (Qiagen, EpiTect plus). 
hTERT promoter hypermethylation and CIMP status were 
then determined as previously described [4, 18].
Fluorescence in situ hybridization (FISH)
ALT status was determined by telomere FISH using the 
Telomere PNA FISH Kit/Cy3 (Dako, Burlington, ON, CA) 
following a generalized protocol as previously described 
[37]. Telomere FISH was performed on 5-μm sections of 
pediatric ependymoma FFPE tissue microarrays containing 
tumor samples in triplicate alongside normal tissue controls 
and ALT-positive high-grade glioma as a positive control. 
Positivity was defined as showing very bright, intranuclear 
foci in at least 1 % out of the 200 total cells quantified per 
core, as well as having at least two cores scored. Scoring 
was performed on a Nikon Eclipse E400 fluorescent micro-
scope (Nikon Instruments, Toronto, ON, CA) with appro-
priate filters at 1,000× magnification.
C11orf95-RELA fusion status was determined using 
‘break-apart’ probes for the RELA gene as previously 
described [26]. FISH was performed on 5-μm sections of 
FFPE tissue. RP11-642F7 probe was labeled with spectrum 
green, while CH17-211O12 probe was labeled with spec-
trum orange. The BAC from the hydatidiform mole (CH17-
211O12) was created at BACPAC Resources by Drs. 
Mikhail Nefedov and Pieter J. de Jong using a cell line cre-
ated by Dr. Urvashi Surti. Fusion positivity was defined as 
more than 25 % of 200 quantified cells showing a ‘break-
apart’ event. Scoring was performed on a Nikon Eclipse 
E400 fluorescent microscope (Nikon Instruments, Toronto, 
ON, CA) with appropriate filters at 1,000× magnification.
Immunohistochemistry
To assess ALT status using ATRX expression, immuno-
histochemistry was performed as previously described 
[15]. 5-μm sections of pediatric ependymoma FFPE tissue 
microarrays containing tumor samples in triplicate along-
side numerous control tissues were stained with rabbit anti-
human ATRX antibody (HPA001906, Sigma-Aldrich) at a 
concentration of 1:600 overnight at 4 °C. The sections were 
scored for nuclear positivity based upon distribution (0, 
0–25, >50) and intensity (light, strong). Samples were con-
sidered positive if two or more cores were scorable and if 
all scored cores showed more than 25 % of nuclei staining 
strongly, suggesting a lack of ATRX mutations and there-
fore lack of ALT. Cores were considered negative only if 
normal endothelial cells stained strongly, as these served 
as internal positive controls for each core. An ALT-posi-
tive high-grade glioma was stained in parallel as a positive 
control.
C-circle assay
C-circle assay was used to determine the prevalence of ALT 
in patient samples as previously described [11]. Following 
DNA extraction from 51 FFPE samples using the Recov-
erAll™ Total Nucleic Acid Isolation Kit for FFPE (Life 
Technologies, Burlington, ON, CA), 16 ng of DNA was 
incubated in master mix containing 5 U of Φ29 polymerase 
for 8 h at 30 °C to allow for C-circle amplification. Quan-
titative polymerase chain reaction (qPCR) was then run on 
2 ng of Φ29 polymerase amplified and non-amplified DNA 
in triplicate using a Lightcycler 480 (Roche). qPCR condi-
tions used were 95 °C for 15 min followed by 35 cycles 
of 95 °C for 15 s and 54 °C for 2 min. The presence of 
C-circles was determined by calculating a ΔmeanCp value 
between triplicate Φ29 polymerase amplified and non-
amplified runs for each sample. Samples with a ΔmeanCp 
value greater than +0.2 were considered C-circle posi-
tive while samples with a ΔmeanCp value less than −0.2 
were considered C-circle negative. ALT-positive fibroblasts 
(GMA47) were used as a positive control, while ALT-neg-
ative cervical cancer cells (HeLa) were used as a negative 
control.
Cell lines
Established BXD-1425EPN (BXD) supratentorial pediatric 
ependymoma cells were acquired and grown as previously 
described [45]. R254 cells were derived from a supratento-
rial pediatric ependymoma and cultured as an established 
cell line in DMEM/F12 (Invitrogen, Burlington, ON, CA) 
supplemented with 15 % fetal bovine serum (Invitrogen) 
and 1× penicillin/streptomycin (Invitrogen). E520 TICs 
were derived from an infratentorial pediatric ependymoma 
and cultured as previously described [18].
All three cell lines were further characterized for hTERT 
promoter mutations, hTERT promoter hypermethylation 
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and telomerase activity. Supratentorial lines (BXD, R254) 
were characterized for C11orf95-RELA fusion status and 
previously reported copy number alterations, while E520 
infratentorial cells are known to be Group A/CIMP (+) 
[18].
SNP array hybridization and data analysis
Genomic DNA from ependymoma cell lines R254 and 
BXD was hybridized to the CytoScan HD Array (Affym-
etrix, Santa Clara, CA, USA). DNA digestion, labeling 
and array hybridization was performed by The Centre 
for Applied Genomics (TCAG) at The Hospital for Sick 
Children (Toronto, ON, Canada). CEL files with raw chip 
intensity data were analyzed for copy number alterations 
at specific loci previously reported to be associated with 
ependymoma using segmentation algorithm in Partek 
Genomics Suite (v6.6). Copy number was inferred from 
differences between the two cell lines and HapMap base-
line. Diploid copy number was assumed between 1.5 and 
2.5 copies. All remaining parameters were used at default 
settings.
In vitro telomerase inhibition
BXD (5 × 105), R254 (1 × 105) and E520 (1 × 105) cells 
were seeded weekly in P100 plates (BD Biosciences, Mis-
sissauga, ON, CA) with fresh media containing either 
5 µM of the telomerase inhibitor Imetelstat (Geron, Menlo 
Park, CA, USA) or scrambled mismatch oligonucleo-
tide control (Geron) in parallel with an untreated control. 
Imetelstat consists of a palmitoylated 13-mer thiophospho-
ramidate oligonucleotide sequence (5′-Palm-TAGGGTTA 
GACAA-3′) with complementarity and high affinity to the 
hTR of telomerase that directly inhibits telomerase activ-
ity, while the mismatch control differs by four residues 
(5′-Palm-TAGGTGTAAGCAA-3′). Untreated, mismatch 
control and Imetelstat treatment groups had media con-
taining the respective compounds replenished midweek. 
At the end of each week, cell number and viability were 
determined using the Vi Cell XR cell counter (Beckman 
Coulter, Mississauga, ON, CA), cell pellets were collected 
for subsequent analysis and the appropriate number of cells 
for each cell line was replated for further treatment until 
growth arrest was observed. Population doublings were 
assessed using the formula: (number of cells collected/
number of cells seeded)/log 2. All experiments were per-
formed in triplicate.
For MST-312 (Sigma-Aldrich, Oakville, ON, CA) tel-
omerase inhibition, 1 × 105 cells were seeded in 6-well 
plates (BD Biosciences, Mississauga, ON, CA) and left 
overnight to attach in triplicate for each dose. MST-312 
was administered in varying doses (0–4 µM) for 72 h and 
cell number and viability were determined using the Vi Cell 
XR cell counter (Beckman Coulter, Mississauga, ON, CA). 
Cell pellets were also collected at each dose for telomerase 
activity assessment. Effective doses were then chosen for 
BXD (2 µM), R254 (2 µM) and E520 (4 µM) cells for sub-
sequent senescence, γH2AX and cell cycle analysis.
Telomere restriction fragment (TRF) assay
Telomere length was determined using the TeloTAGGG 
Telomere Length Assay Kit (Roche) according to manu-
facturer’s instructions. 1.5 µg of DNA was used per sam-
ple and average telomere length was calculated by divid-
ing each lane into 20 equally sized rectangles, quantifying 
density with ImageJ software (http://rsb.info.nih.gov/ij/) 
and using the formula length = Σ(density)/Σ(density/dis-
tance on gel). Appropriate positive and negative controls 
provided with the kit were included with each run.
Immunofluorescence
Immunofluorescence was performed as previously described 
[41]. Primary antibody used was γH2AX (1:1,000, Mil-
lipore). Slides were viewed and images captured using 
an Eclipse E400 fluorescent microscope equipped with a 
DXM1200F camera (Nikon, Melville, NY, USA). Image 
analyses were performed using ImageJ software (http://rsb.
info.nih.gov/ij/). For γH2AX foci quantification, 50 cells in 
random fields of view were scored in triplicate for untreated, 
mismatch control and Imetelstat-treated cells.
β-Galactosidase assay
Senescence was determined using a β-galactosidase Stain-
ing kit (Cell Signalling Technology, Beverly, MA, USA). 
1 × 105 untreated, mismatch control or Imetelstat-treated 
cells were seeded on glass coverslips and left overnight to 
attach in triplicate. Following kit instructions, images were 
captured using an Eclipse E400 microscope (Nikon) and 50 
cells in random fields of view were quantified for blue col-
oration indicating senescence.
Clonogenic assay
R254 cells that were either untreated, or treated with mis-
match or Imetelstat, were seeded in P100 plates (BD Bio-
sciences) in triplicate and cultured for 2 weeks. Media 
was removed and cells were fixed and stained with crystal 
violet solution containing 2.5 mg/ml crystal violet (Sigma-
Aldrich, Oakville, ON, CA), 80 % methanol (Sigma-
Aldrich) and 3.5 % formaldehyde (Sigma-Aldrich). Crys-
tal violet solution was then washed off and colonies were 
manually quantified.
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Flow cytometry
Approximately 5 × 105 to 1 × 106 cells were prepared for 
cell cycle arrest analysis as previously described [41]. A 
Becton–Dickinson LSRII 15-color analyzer (Mississauga, 
ON, CA) was used to detect 1 × 104 events in triplicate for 
untreated and MST-312 treated cells. Collected data were 
then analyzed using FlowJo flow cytometry analysis soft-
ware (http://www.flowjo.com/).
Sphere-forming assay
Sphere-forming analyses were performed as previously 
described [33]. In brief, E520 neurospheres were disso-
ciated and plated in quadruplicate in a 96-well plate (BD 
Biosciences) in 100 μL of stem cell media in triplicate. 
Cell dilutions ranged from 200 cells/well to 4 cells/well. 
Spheres were allowed to form for 14 days at 37 °C and then 
sphere number was quantified for each well and plotted 
against the number of cells seeded per well. In addition, the 
percentage of wells not containing spheres was calculated 
and plotted against the number of seeded cells per well. 
Regression lines were plotted and the x-intercept was deter-
mined, representing the number of cells required to form 
one tumor sphere in every well.
Orthotopic telomerase inhibition
5.0 × 104 E520 cells transfected with luciferase using len-
tivirus were suspended in 3 μL of stem cell media and 
injected into the cerebral hemisphere (1 mm to the right of 
the midline, 1.5 mm anterior to the lambdoid suture and 
3 mm deep) of 8- to 12-week-old male and female NSG 
mice as previously described [45]. Following 7 days, mice 
were injected subcutaneously with D-luciferin (Goldbio, 
St. Louis, MO, USA) at a concentration of 0.15 mg/mg to 
allow imaging using an IVIS Imaging System (PerkinElmer, 
Woodbridge, ON, CA). Mice with detectable tumors were 
randomly assigned into either PBS (n = 9) or Imetelstat 
(n = 8) treatment groups and injected intraperitoneally thrice 
weekly with Imetelstat (30 mg/kg) or PBS equivalent. Upon 
killing, tumors were both fixed in formalin and snap-frozen 
for subsequent analysis. Animal procedures were approved 
by the Sick Kids Animal Care Committee and performed in 
a facility approved by the Canadian Council of Animal Care.
Subcutaneous telomerase inhibition
5.0 × 104 E520 TICs suspended in 200 µl of 1:1 Matrigel 
(BD Biosciences)/PBS (Invitrogen) solution were injected 
into the flank of NOD/SCID/Gamma (NSG) immunodefi-
cient mice. Following 9 days, tumor presence was validated 
by palpation and mice possessing tumors were randomly 
assigned into PBS or Imetelstat treatment groups (n = 6/
group). Mice were then injected intraperitoneally three 
times weekly with Imetelstat (30 mg/kg) or PBS equiva-
lent. Tumor volume was quantified weekly using digital 
calipers and all mice were killed following 5 weeks of 
treatment. Tumors were both fixed and snap-frozen for 
subsequent analysis. Animal procedures were approved 
by Sick Kids Animal Care Committee and performed in a 
facility approved by the Canadian Council of Animal Care.
Tumorigenicity assay
3.0 × 104 E520 untreated or Imetelstat-pretreated TICs 
(34 weeks) were suspended in 2 μl of stem cell media and 
injected into the cortex (1 mm to the right of the midline, 
1.5 mm anterior to the lambdoid suture and 3 mm deep) of 
NSG immunodeficient mice as previously described [45]. 
Mice were monitored daily until signs of morbidity were 
observed and were killed for subsequent histopathologi-
cal analysis. Mice not displaying signs of morbidity were 
killed following 90 days post-injection. Brains from mice 
were removed, fixed in formalin and assessed by a neuro-
pathologist (CH) for tumor growth. Two mice were lost 
to follow-up. Animal procedures were approved by Sick 
Kids Animal Care Committee and performed in a facility 
approved by the Canadian Council of Animal Care.
Statistical analysis
Statistical analyses were performed using SPSS v21 (IBM 
Corp, Armonk, NY, USA). Kaplan–Meier methods were 
used to determine survival statistics on patient progression 
and survival based on age (>3 years), sex, tumor location, 
grade, level of resection, radiation, chemotherapy and tel-
omerase status, as well as mouse survival following ortho-
topic injection. Log-rank tests were performed to determine 
univariate significance (p ≤ 0.05) of Kaplan–Meier survival 
curves. Unpaired, two-tailed Student’s t test was used to 
determine statistical significance (p ≤ 0.05) of cell counts, 
viability, immunofluorescent positivity, colony and sphere 
formation, senescence, tumor growth and telomere length. 
Chi squared tests were performed when testing for signifi-
cant (p ≤ 0.05) associations between biological features.
Results
Telomerase is the sole telomere maintenance mechanism 
in pediatric ependymoma and predicts recurrence 
and survival
To determine the prevalence of telomerase activity in pedi-
atric ependymoma, TRAP assays were performed on 36 
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fresh-frozen primary ependymoma cases. 64 % (23/36) 
of ependymomas were found to possess active telomerase 
(Table 1). Since recently identified mutations and hyper-
methylation within the hTERT promoter have been sug-
gested to drive telomerase activation, the association of 
telomerase activity with either of these mechanisms was 
investigated [4, 12, 13]. While none (0/18) of the pediat-
ric ependymomas screened for C228T and C250T hTERT 
promoter mutations using a Taqman assay were found to 
harbor mutations, 67 % (16/24) of ependymomas were 
hypermethylated at the hTERT promoter upon sequenom 
analysis (Table S1). Hypermethylation was not signifi-
cantly (p = 0.67) associated with telomerase activity within 
our limited cohort.
The association of telomerase activity with recently 
identified subgrouping of infratentorial (CpG island meth-
ylator phenotype (CIMP)) and supratentorial (C11orf95-
RELA fusion) pediatric ependymomas was also inves-
tigated [18, 26, 27, 40]. 78 % (18/23) of infratentorial 
ependymomas were determined to be Group A/CIMP (+) 
upon sequenom analysis (Table S1), while 45 % (5/11) 
of supratentorial cases harbored C11orf95-RELA fusions 
upon interphase FISH (Fig. S1; Table S1). Neither CIMP 
(p = 0.64) nor C11orf95-RELA fusion status (p = 1.00) 
was significantly associated with telomerase activity sug-
gesting that telomere maintenance is independent of sub-
group status.
Kaplan–Meier estimates and log-rank survival analy-
ses were performed to determine whether children whose 
tumors possessed telomerase activity were more likely 
to experience progression or mortality. Children harbor-
ing telomerase-active tumors showed reduced 5-year PFS 
(29 ± 11 vs 64 ± 18 %; p = 0.03) and OS (29 ± 13 vs 
83 ± 15 %; p = 0.05) rates compared to children whose 
tumors lacked telomerase activity (Fig. 1a, b; Table 1). 
Assessment of telomerase activity separately within either 
the supratentorial or infratentorial compartment showed 
activity predicted reduced 5-year PFS within the infratento-
rial region (31 ± 14 vs 64 ± 21 %; p = 0.05). Upon mul-
tivariate survival analysis, TRAP activity was associated 
with the greatest hazard ratio and approached significance 
most closely (HR = 5.67, p = 0.10); however, low cohort 
size limited statistical power (Table S2).
Telomere FISH (n = 56), C-circle analysis (n = 51) 
and ATRX immunohistochemistry (n = 41) were then per-
formed on a combined total of 76 unique primary pediatric 
ependymomas to determine whether ependymomas also 
rely on ALT as a mechanism of telomere maintenance. 
75 % (57/76) of cases were assessed for ALT using more 
than one technique. Interestingly, none of the primary pedi-
atric ependymomas showed evidence of ALT upon telomere 
FISH (Fig. 1c, d; Table S1), C-circle analysis (Table S1), or 
ATRX staining (Fig. S2; Table S1). In addition, although 
previous work has shown that 100 % of recurrent epend-
ymomas (8/8) possessed active telomerase, the prevalence 
of ALT in recurrent ependymoma remained to be eluci-
dated [29]. Using telomere FISH (n = 16) and ATRX stain-
ing (n = 12), with 33 % (7/21) of cases being assessed with 
both techniques, we found that recurrent ependymomas did 
not rely on ALT as a mechanism of telomere maintenance 
Fig. 1  Telomerase activity 
predicts progression and sur-
vival in pediatric ependymoma, 
while no cases rely on ALT to 
maintain telomeres. Kaplan–
Meier analysis (n = 36) showed 
children with ependymomas 
possessing active telomerase 
(positive) had reduced pro-
gression-free survival (a) and 
overall survival (b) compared to 
children whose tumors lacked 
active telomerase (negative). 
Telomere FISH showed a lack 
of ultrabright intranuclear foci 
(c) in 56 primary ependymo-
mas indicating a lack of ALT, 
while these foci (arrow) could 
be observed in an ALT-positive 
high-grade glioma positive 
control (d). Significance was 
determined using log-rank 
statistics and images were taken 
at 1,000× magnification. PFS 
progression-free survival, OS 
overall survival
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(Table S1). Since telomerase activity comprises a hallmark 
event observed in the majority of pediatric ependymomas 
and specifically identifies high-risk patients with decreased 
PFS and OS, telomerase inhibition was investigated as a 
novel therapeutic strategy.
Telomerase inhibition attenuates proliferation in vitro 
by shortening telomeres and inducing senescence
We investigated the effect of telomerase inhibition on pro-
liferation using two established pediatric ependymoma cell 
lines (BXD, R254) and a primary TIC line (E520). Charac-
terization of these cell models for hTERT promoter muta-
tions and hypermethylation, telomerase activity, subgroup 
affiliation and previously reported copy number alterations 
indicated these cell models share characteristic features 
common to pediatric ependymoma (Table S3) [14, 23]. 
BXD, R254 and E520 cells treated with the telomerase 
inhibitor Imetelstat showed decreased proliferation follow-
ing prolonged treatment compared to untreated and scram-
bled oligonucleotide mismatch control cells (Fig. 2a–c; 
p < 0.05). All three in vitro models treated with Imetelstat 
displayed significant reduction of telomerase activity 
throughout treatment (Fig. 2d–f), as well as progressive 
telomere shortening compared to control cells (Fig. 2g–i). 
Onset of growth arrest was not associated with initial tel-
omere length and a lack of ALT-associated banding pat-
terns comprised of long and heterogeneous telomere length 
upon TRF (Fig. 2g–i) indicated that cells did not convert 
to an ALT phenotype as an escape mechanism despite pro-
longed treatment duration.
Once telomeres erode to a critically short length, 
they become dysfunctional and activate a DNA damage 
response mediated by γH2AX, which ultimately results in 
senescence [6]. All three cell models treated with Imetelstat 
showed evidence of γH2AX foci in ~40–60 % of cells by 
the end of treatment, while almost none of the untreated or 
mismatch control cells showed evidence of DNA damage 
(Fig. 3a–c; p < 0.05). BXD, R254 and E520 cells showed 
a progressive increase in the proportion of Imetelstat-
treated cells undergoing senescence, whereby 60, 80 and 
30 % of cells, respectively, underwent senescence by the 
end of treatment (Fig. 3d–f; p < 0.05). Although R254 cells 
showed a 15 % (p < 0.05) increase in apoptosis in the last 
3 weeks of treatment, BXD and E520 cells did not undergo 
any significant cell death (data not shown).
Previous studies have shown Imetelstat may exert off-
target cytoskeletal effects characterized by cell rounding 
morphological changes, loss of adherence and reduced 
proliferation [22]. To determine whether similar off-target 
effects contributed to the observed results, cell surface area 
was quantified at the end of Imetelstat treatment for each 
cell line (Fig. S3). Cell surface area was either unchanged 
or increased in all three cell models, suggesting that the 
previously reported off-target cytoskeletal effects did not 
influence the observed results.
To validate telomerase as an effective therapeutic target 
in pediatric ependymoma, cells were treated with a sec-
ond telomerase inhibitor, MST-312. Although low-dose, 
long-term (>28 day) MST-312 treatment has been shown 
to reduce proliferation and shorten telomeres, high-dose, 
short-term (3 day) MST-312 treatment reduces prolifera-
tion and induces DNA damage localized to telomeres [31, 
41]. Following 72-h treatment of BXD, R254 and E520 
ependymoma cells with MST-312, all three cell lines 
showed a dose-dependent decrease in proliferation (Fig. 
S4a–c; p < 0.05) and telomerase activity (Fig. S4d–f). 
Growth arrest was not associated with a reduction in viabil-
ity or increase in senescence (data not shown). However, 
an increase in γH2AX-positive nuclei was observed in 
all three cell lines (Fig. S4g–i), with two of the three cell 
models (BXD, R254) displaying an accumulation of cells 
within the G2 cell phase, suggestive of G2/M cell cycle 
arrest (Fig. S4j–l). Imetelstat was subsequently chosen to 
study telomerase inhibition in vivo due to its defined mech-
anism and progress in clinical trials.
Telomerase inhibition shortens telomeres and reduces 
tumor growth in vivo
To study the effect of telomerase inhibition in vivo, 
E520 TICs were used to generate an orthotopic model of 
pediatric ependymoma. Established tumors treated with 
Imetelstat did not result in improved overall survival 
(Fig. S5a; p = 0.59) or reduced tumor growth (Fig. S5b, 
c; p > 0.05) compared to control mice treated with PBS. 
Since Imetelstat-treated tumors failed to show significant 
signs of telomerase inhibition compared to PBS control 
mice (Fig. S5d), we concluded that either Imetelstat was 
not crossing the blood–brain barrier (BBB) effectively in 
our model or the E520 cells grew too quickly resulting in 
death of the animals before telomere attrition could occur 
sufficiently for a therapeutic effect. Thus, as an alterna-
tive, telomerase inhibition was assessed in a subcutane-
ous model to circumvent BBB penetration issues and 
permit longer treatment duration in this aggressive tumor 
model.
Imetelstat-treated mice were found to possess subcu-
taneous tumors 40 % smaller than vehicle-treated mice 
following 5 weeks of treatment (Fig. 4a, b; p = 0.03). 
Imetelstat-treated tumors also weighed 35 % less than 
vehicle-treated mice (Fig. 4c; p = 0.04). Mice treated with 
the telomerase inhibitor Imetelstat were found to have sig-
nificantly (p < 0.01) shorter average telomere lengths com-
pared to PBS control mice (5.3 ± 0.96 vs 7.6 ± 0.66 kbps) 
(Fig. 4d). In addition, a lack of long and heterogeneous 
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telomere length upon TRF once again indicated that despite 
prolonged treatment, tumors did not convert to an ALT 
phenotype (Fig. 4d). There was a significant correlation 
(r = −0.65, p = 0.02) between telomere length and tumor 
mass, whereby tumors with the smallest mass also pos-
sessed the shortest telomeres (Fig. 4e). These results high-
light that telomerase inhibition can reduce pediatric epend-
ymoma growth in vivo.
Telomerase inhibition reduces self-renewal and abolishes 
tumorigenicity in pediatric ependymoma
Since pediatric ependymomas are highly recurrent, we 
thought it was critical to determine whether telomerase 
inhibition attenuates the self-renewal and tumorigenic 
capacity of cells that may contribute to recurrence. Ime-
telstat induced a progressive decrease in the self-renewal 
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Fig. 2  Imetelstat reduced proliferation, inhibited telomerase and 
shortened telomeres in three pediatric ependymoma cell lines. Pro-
longed Imetelstat treatment of BXD (a), R254 (b) and E520 (c) cells 
inhibited proliferation following 8, 6 and 16 weeks, respectively. 
TRAP assay showed that BXD (d), R254 (e) and E520 (f) cells 
treated with Imetelstat had a marked reduction in telomerase activ-
ity throughout treatment compared to untreated and mismatch con-
trol cells as indicated by a reduced banding pattern. TRF assay also 
showed BXD (g), R254 (h) and E520 (i) cells treated with Imetelstat 
underwent a progressive decrease in telomere length as determined 
by lower banding compared to untreated and mismatch control cells 
as treatment duration increased (weeks). Positive control (+) for 
TRAP and TRF assays were kit provided telomerase-positive lysate 
and control DNA, respectively. Negative control (−) for TRAP and 
TRF assays were lysis buffer and sterile water, respectively. TRF lad-
der represents kbps. U untreated, M mismatch, I Imetelstat, IC PCR 
internal control, L ladder
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Fig. 3  Imetelstat-treated cells displayed an activated DNA damage 
response associated with a progressive increase in senescence. Immu-
nofluorescence showed BXD (a), R254 (b) and E520 (c) cells had 
increased γH2AX staining compared to untreated and mismatch con-
trol cells following 27, 17 and 34 weeks of treatment, respectively. 
β-galactosidase (β-gal) staining showed a progressive increase in cells 
undergoing senescence in BXD (d), R254 (e) and E520 (f) cells. All 
images were taken at 200× magnification and scale bars represent 
either 50 or 100 μm as indicated. Error bars represent ± SD of the 
mean. Asterick represents significance at p < 0.05 compared to both 
untreated and mismatch control
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of R254 cells throughout treatment, achieving complete 
inhibition of self-renewal following 17 weeks (Fig. 5a; 
p < 0.05). Similarly, using a sphere-forming assay to sur-
vey the self-renewal of E520 TICs, Imetelstat inhibited 
self-renewal by 75 % compared to untreated or mismatch 
control cells following 34 weeks of treatment (Fig. 5b; 
p < 0.01). Finally, untreated and Imetelstat-pretreated E520 
cells (34 weeks) were injected intracranially into mice to 
assess whether telomerase inhibition attenuates tumo-
rigenicity in vivo. Following 90 days, none of the mice 
injected with Imetelstat-pretreated cells showed any clinical 
evidence of tumor formation, while all of the mice injected 
with untreated E520 cells required killing (Fig. 5c). Histo-
pathological examination revealed tumor formation in all 
mice that received E520 controls, while none of the mice 
injected with pretreated cells showed evidence of tumor 
formation (Fig. 5d, e). Therefore, these observations sug-
gest loss of self-renewal and tumor initiating capacity of 
ependymoma cells in vitro and in vivo following telomer-
ase inhibition.
Discussion
Our work has shown that pediatric ependymomas rely 
exclusively on telomerase activity as a mechanism of tel-
omere maintenance. Furthermore, telomerase activity is 
associated with increased progression and when inhibited, 
results in the loss of proliferation, self-renewal and tumo-
rigenicity. These findings provide novel insight into the 
importance of telomerase as a predictor of outcome and as 
a therapeutic target in pediatric ependymoma.
This study is unique because we have utilized TRAP, 
the gold standard of telomerase enzymatic activity detec-
tion, as a method of studying telomerase activity in pediat-
ric ependymoma. TRAP is superior to previously utilized 
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methods of telomerase detection in pediatric ependymoma 
as it specifically detects telomerase activity in ependymo-
mas. There are currently no specific antibodies for telom-
erase available [44] and hTERT mRNA analysis has shown 
poor correlation between TERT mRNA expression levels 
and enzymatic activity, albeit this discordance has not been 
shown specifically in pediatric ependymoma [19]. Our 
work has also shown that hTERT promoter mutations and 
methylation are not good surrogates for telomerase activ-
ity in pediatric ependymoma. The TRAP assay is a sim-
ple and robust method, utilizing only 1 μg of protein (or 
~2 mm3 piece of tissue) for activity detection and could be 
introduced into clinical practice as a method to undeniably 
assess functional telomerase.
By comprehensively investigating telomere maintenance 
mechanisms in pediatric ependymoma, we have found that 
these tumors rely on telomerase to maintain telomeres or 
do not maintain telomeres at all, as none of the tumors 
screened for ALT were positive. Furthermore, to recur, 
pediatric ependymomas are highly reliant on telomerase 
(Fig. 1a). A previous study highlights the importance of tel-
omerase for recurrence, whereby all recurrent ependymo-
mas tested (8/8) had detectable telomerase activity [29], 
while none of the recurrent ependymomas screened (0/21) 
in our study showed evidence of ALT. Therefore, pediat-
ric ependymomas lacking telomerase activity are unable 
to maintain telomeres and proliferative indefinitely, sug-
gesting that less aggressive therapeutic intervention may 
be offered for children with telomerase-negative tumors. 
In fact, previous work has shown that pediatric gliomas 
lacking telomere maintenance undergo telomere shorten-
ing upon recurrence, and where primary tumors possessed 
short telomeres, spontaneous growth arrest was observed 
[37]. Telomerase activity was also not associated with 
CIMP or C11orf95-RELA fusion status, suggesting tel-
omerase inhibition may be a useful therapeutic strategy 
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with broad applicability. Our results show that in pediatric 
ependymoma, telomerase is an abundant target with few 
escape mechanisms thus representing an ideal therapeutic 
target that may aid in preventing recurrence.
Although numerous studies have shown reduced pediat-
ric ependymoma growth in vitro, our study is one of the 
first to show significant growth inhibition in vivo [8, 18, 21, 
24, 30, 42]. Telomerase inhibition reduced proliferation in 
two established cell lines and a primary TIC line (Fig. 2a–
c) through shortening of telomeres (Fig. 2g–i) and induc-
tion of senescence (Fig. 3d–f). Imetelstat was also shown 
to reduce established tumor growth by 35–40 % with a 
correlation between shortened telomeres and tumor mass 
(Fig. 4). In both in vitro and in vivo models, despite pro-
longed telomerase inhibition, there was also no evidence 
that ependymoma cells switched to ALT to maintain their 
telomeres. Telomerase inhibition also appeared less effi-
cacious toward reducing proliferation and inducing senes-
cence of Group A/CIMP (+) cells compared to supraten-
torial cells (Figs. 2, 3), suggesting a subgroup-dependent 
efficacy of telomerase inhibition, however these observa-
tions could be attributable to differences in culture condi-
tions and require further investigation to provide any sound 
conclusions. Telomerase inhibition significantly reduced 
self-renewal of both supratentorial and infratentorial cell 
models (Fig. 5a, b) and completely inhibited the tumo-
rigenicity of CIMP-positive infratentorial ependymoma 
TICs in an orthotopic xenograft model (Fig. 5c–e). These 
results corroborate previous studies showing that Imetelstat 
can target cells with robust self-renewal and tumor initi-
ating capacity in numerous cancer types including brain 
cancer, and suggest that these tumorigenic cell populations 
are highly dependent upon telomerase for continued pro-
liferation [2, 5, 20]. Since telomerase inhibition requires a 
prolonged treatment duration to senesce cells and appears 
much more effective at attenuating self-renewal and tumo-
rigenicity than proliferation, telomerase inhibition repre-
sents an ideal therapeutic approach following surgery when 
there is minimal residual disease, and should be taken into 
consideration in future clinical trials.
Despite these promising results, there are a number of 
limitations to this study. First and foremost, the requirement 
of fresh-frozen tissue to detect telomerase activity has lim-
ited our cohort size. In addition, although it has previously 
been shown that Imetelstat can cross the BBB in mice, Ime-
telstat was unable to effectively inhibit established ortho-
topic tumor growth, suggesting either poor BBB penetration 
in our model and/or rapid growth of our aggressive tumor 
model that prevented sufficient treatment duration [20]. 
Future clinical trials must take into consideration the BBB 
penetration of Imetelstat; however, our data provides impor-
tant proof-of-principle evidence that telomerase inhibition 
represents a promising therapeutic strategy to pediatric 
ependymoma. Future work involves validating the prognos-
tic potential of telomerase in a larger and prospective cohort, 
as well as utilizing telomerase inhibition as a combinational 
therapy and improving drug delivery to the brain.
In summary, telomerase is critical for the maintenance 
of telomeres in pediatric ependymoma and for sustaining 
cells with limitless proliferation that may contribute to 
recurrence. Telomerase inhibition represents a potentially 
promising maintenance therapy for telomerase-positive 
pediatric ependymomas following surgical resection when 
there is minimal residual disease.
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